
Consort Medical announced that it has agreed terms to acquire the entire issued and to be issued share capital of Aesica Pharmaceuticals for £230 million.

Consort Medical announced that it has agreed terms to acquire the entire issued and to be issued share capital of Aesica Pharmaceuticals for £230 million.

LABOCHIM SpA completes construction on multipurpose high-potent API plant in Milan.

CPhI Worldwide releases "25 pharma stories made at CPhI" for 25th anniversary.

Dow Corning will present new silicones for topical ingredients, topical excipients, transdermal adhesives, and oral APIs at booth 5R31.

Lucideon announced that it is investing £1.5 million to expand its headquarters to include pharmaceutical quality-control testing laboratories.

West Pharmaceutical Services announced that they will form a new facility in Ireland for the production of insulin injector cartridge packaging components.

SCHOTT will present the adaptiQ ready-to-use vials, syriQ prefilled syringes, and the TopPac Polymer syringes at CPhI Worldwide 2014 in Paris.

Partnership is awarded for licensing of low-cost vaccine for the treatment of bacterial meningitis.

In response to the Ebola outbreak, EMA has started reviewing Ebola treatments in the development pipeline.

In a highlight from the second annual "CPhI 2014 Expert Industry Annual Report: Part I," Vijay Shah of Piramal Enterprises discusses the benefits of adopting greener practices.

CHMP has recommended 15 new medicines for approval and three extensions of indication.

International Organization for Standardization's environmental management standard 14001 has entered the draft stage, allowing public commentary on revisions.

Global Controlled Release Alliance, a partnership between Dow Pharma & Food Solutions and Colorcon, will present METHOCEL DC2 compressible hydroxypropyl methylcellulose at CPhI Worldwide 2014.

NIH continues funding for tissue chips to be used in the development of therapeutics.

USP expresses its support for a consensus-based global approach to the naming of biologics.

FDA report details risk mitigation projects.

Formulation will utilize Catalent?s OSDrC OptiDose multicore drug-delivery platform.

Meeting increasing expectations and escalating regulatory requirements to protect patients.

Acorda Therapeutics acquired Civitas Therapeutics for $525 million, giving Acorda all the rights to CVT-301, a Phase III candidate for off episodes of Parkinson's disease.

The campaign supports pharmaceutical growth in India and serves to highlight the value proposition that Indian pharmaceuticals present.

AstraZeneca's global biologics research group, MedImmune, received FDA Fast Track designation for MEDI3902, for the prevention of nosocomial pneumonia.

AdPack is an efficient, economical, and safe solution for the protection of moisture-sensitive pharmaceuticals, such as tablets and capsules, inside the packaging.

In its 2014 annual report from CPhI Worldwide, industry experts suggest that the pharmaceutical industry needs an evolutionary approach to remain sustainable in the longer term.

Avalon Ventures and GSK add two more companies to their launch list of early-stage life-science companies.

Almac Group recently appointed two key positions in marketing: Market Development Director, and Senior Market Insight Director.

DuPont Nutrition & Health has added a new pharmaceutical excipient to the portfolio of ingredients for CPhI Worldwide 2014, in Paris this October.

Alchem International announced that it will continue to market and support Tropane Alkaloid APIs despite earlier reports.

CALIXAR and VirPath use new manufacturing techniques to create a vaccine for the pandemic flu, influenza A (H1N1), available in 2015.

Regulations, product protection, and cost management are top concerns of supply chain decision makers.

Merck KGaA will expand the reach of its EMD Millipore division with the purchase of life-sciences company Sigma-Aldrich.